Previsioni
Il prezzo obiettivo medio degli analisti è 54,08 € (+89,42%). La mediana è 55,60 € (+94,75%).
| Acquista |
14 |
| Mantieni |
0 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Pharvaris presents Deucrictibant ahead of market launch after strong phase‑III data
Pharvaris unveiled final plans for Deucrictibant at the Morgan Stanley Healthcare Conference. The oral HAE drug showed Phase‑III efficacy of 87% in HAE types 1 and 2 (83% in the extended population). The company is targeting U.S. approval for on‑demand treatment with a PDUFA target date of April 2027 and is preparing a prophylactic indication thereafter. Management highlighted a favorable safety profile versus competing oral therapies, plans to build a commercial organization (target: ~90 employees) and expects liquidity into mid‑2028 in the base case. Additional data from CREATE and an open‑label extension study are expected to be released in the coming months. » Altro su de.investing.com
Pharvaris shows phase‑III success: Deucrictibant reduces HAE attacks by 87%
At the Cantor Fitzgerald conference Pharvaris presented phase‑III data (CHAPTER‑3) showing an 87% reduction in hereditary angioedema attacks with the oral B2‑receptor antagonist Deucrictibant. The study included patients from six continents and used an extended‑release formulation that may explain the improved efficacy profile. Safety questions remain: two grade‑3 elevations in liver enzymes and one serious laryngeal event were reported, though the company considers the overall profile comparable to existing prophylactics. Pharvaris plans to launch the on‑demand treatment on April 8, 2025, and aims to file for approval for prophylaxis in the first half of 2025, supported by a targeted commercial platform for bradykinin‑mediated angioedemas. » Altro su de.investing.com
Pharvaris: oral HAE drug deucrictibant shows strong phase‑III data
Deucrictibant reduced HAE attacks by 87% in the phase‑III prophylaxis study in type‑1/ type‑2 patients (83% in the overall population) and replicated earlier results in a larger, global cohort. Pharvaris expects a PDUFA date for the on‑demand formulation on April 23 and plans to submit the regulatory application for the prophylaxis version in H1 2025. Two cases of elevated liver enzymes were reported but, according to management, are comparable to known risks; long‑term safety is being investigated in the open‑label extension study CHAPTER‑4. Commercially, the company intends to target treatment‑naive patients as well as users of ORLADEYO and injectable therapies. » Altro su de.investing.com
Pharvaris rises sharply after positive phase‑3 data for HAE drug
Pharvaris reported statistically significant topline results from the pivotal phase‑3 study CHAPTER‑3: Deucrictibant XR reduced the mean monthly HAE attack rate by 83% versus placebo (p<0.0001) and lowered the rate in HAE type 1/2 by 87%. All secondary endpoints were significant and the safety profile proved well tolerated. The company intends to use the data for regulatory submissions, including a New Drug Application in the US in the first half of 2027, and the stock then reached a new 52‑week high. » Altro su de.investing.com
Pharvaris: Phase‑3 study of Deucrictibant XR meets primary endpoint and markedly reduces HAE attacks
Pharvaris reports that the Phase‑3 CHAPTER‑3 study of Deucrictibant XR met its primary endpoint for prevention of hereditary angioedema (HAE) attacks. A once‑daily 40 mg dose reduced the mean monthly attack rate across all three HAE types by 83% versus placebo and by 87% in HAE types 1 and 2; all secondary endpoints were also statistically significant. Protection began in the first week of treatment and was maintained over 24 weeks. Deucrictibant XR was well tolerated, with no treatment‑related serious adverse events. Pharvaris plans to use the CHAPTER‑3 data to support regulatory filings and intends to submit a New Drug Application to the FDA in the first half of 2027. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2022, Pharvaris Aktie ha già distribuito 0,10 € di dividendi. L'ultimo pagamento è avvenuto a luglio 2022.
Dati finanziari
Nell'ultimo trimestre, Pharvaris Aktie ha registrato ricavi pari a 0 € e un utile netto di -47,41 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | 0 | - |
| Utile netto | -47,41 Mln | 27,67% |
| EBITDA | -49,99 Mln | 34,33% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 2,02 Mld € |
Numero di azioni | 70,79 Mln |
Massimo/minimo a 52 settimane | 39,42 € - 21,10 € |
| Dividendi | No |
Beta | -2,48 |
Rapporto P/E | -10,29 |
Rapporto PEG | -2,45 |
Rapporto P/B | 7,57 |
Rapporto P/S | 0,00 |
Profilo aziendale
Pharvaris N.V., una società biofarmaceutica in fase di sviluppo clinico, si concentra sullo sviluppo e sulla commercializzazione di terapie per malattie rare. La società sviluppa PHA121, un antagonista a piccola molecola del recettore B2 della bradichinina, attualmente in sperimentazione clinica di Fase II per il trattamento dell'angioedema ereditario (HAE). Sviluppa inoltre PHVS416, una capsula molle a rapido assorbimento e somministrazione on-demand per pazienti che soffrono di attacchi acuti di HAE, in sperimentazione clinica di Fase 2; e PHVS719, una compressa profilattica a rilascio prolungato per pazienti con HAE, in sperimentazione clinica di Fase 1. Opera nei Paesi Bassi, in Svizzera e negli Stati Uniti. La società è stata costituita nel 2015 e ha sede a Leida, nei Paesi Bassi.
| Nome | Pharvaris Aktie |
| CEO | Berndt Modig |
| Sede centrale | Zug,
zh Paesi Bassi |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 05/02/2021 |
| Dipendenti | 148 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | PHVS |
Frankfurt | 9EN.F |
Düsseldorf | 9EN.DU |
München | 9EN.MU |